H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA 02139, USA.
H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA 02139, USA.
Cell Rep. 2018 Apr 3;23(1):282-296.e4. doi: 10.1016/j.celrep.2018.01.088.
Hotspot mutations in splicing factor genes have been recently reported at high frequency in hematological malignancies, suggesting the importance of RNA splicing in cancer. We analyzed whole-exome sequencing data across 33 tumor types in The Cancer Genome Atlas (TCGA), and we identified 119 splicing factor genes with significant non-silent mutation patterns, including mutation over-representation, recurrent loss of function (tumor suppressor-like), or hotspot mutation profile (oncogene-like). Furthermore, RNA sequencing analysis revealed altered splicing events associated with selected splicing factor mutations. In addition, we were able to identify common gene pathway profiles associated with the presence of these mutations. Our analysis suggests that somatic alteration of genes involved in the RNA-splicing process is common in cancer and may represent an underappreciated hallmark of tumorigenesis.
热点突变拼接因子基因在血液系统恶性肿瘤中高频报道,提示 RNA 拼接在癌症中的重要性。我们分析了癌症基因组图谱(TCGA)中 33 种肿瘤类型的全外显子测序数据,鉴定了 119 个具有显著非同义突变模式的剪接因子基因,包括突变过度表达、反复功能丧失(肿瘤抑制因子样)或热点突变谱(癌基因样)。此外,RNA 测序分析揭示了与选定剪接因子突变相关的剪接事件的改变。此外,我们能够确定与这些突变存在相关的常见基因通路谱。我们的分析表明,涉及 RNA 剪接过程的基因的体细胞改变在癌症中很常见,可能代表了肿瘤发生的一个被低估的标志。